Revolution Medicines CFO sells 2,753 shares in plan

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,753 shares of common stock at an average price of $99.4804 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,753 shares of common stock at an average price of $99.4804 per share. The transaction was made pursuant to a pre-established Rule 10b5-1 instruction letter to satisfy tax withholding obligations on vested RSUs. Following the sale, he directly holds 125,512 shares, which include 56,600 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 2,753 shares

Net Sell 1 txn

Insider Anders Jack

Role Chief Financial Officer

Sold 2,753 shs ($274K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,753	$99.4804	$274K

Holdings After Transaction: Common Stock — 125,512 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. Includes 56,600 RSUs.

FAQ

What insider transaction did RVMD’s CFO report in this Form 4?

Revolution Medicines’ CFO Anders Jack reported selling 2,753 shares of common stock in an open-market transaction at an average price of $99.4804 per share. The filing also shows his updated direct holdings after the sale.

Was the RVMD CFO’s share sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023. The plan was set up to satisfy the reporting person’s tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.

How many RVMD shares does the CFO hold after this transaction?

After selling 2,753 shares, Anders Jack directly holds 125,512 shares of Revolution Medicines common stock. This figure reflects his position immediately following the reported transaction, as disclosed in the Form 4, and includes restricted stock units referenced elsewhere in the filing.

What price did the RVMD CFO receive for the shares sold?

The reported open-market sale was executed at an average price of $99.4804 per share. This price represents the weighted average transaction price for the 2,753 shares sold, as specified in the Form 4 transaction details for Revolution Medicines’ common stock.

Does the RVMD Form 4 mention restricted stock units held by the CFO?

Yes. A footnote explains that the CFO’s holdings include 56,600 restricted stock units. It also notes that the Rule 10b5-1 instruction letter was adopted to satisfy tax withholding obligations arising upon the vesting of these RSUs after July 15, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		2,753	D	$99.4804	125,512(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 56,600 RSUs.

	/s/ Jack Anders	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)